1. Kolavenic acid analog restores growth in HSET-overproducing fission yeast cells and multipolar mitosis in MDA-MB-231 human cells
- Author
-
Takashi Toda, Ken-ichi Kimura, Takumu Onodera, Masashi Yukawa, Hiroyuki Koshino, and Naoaki Kurisawa
- Subjects
Programmed cell death ,Clinical Biochemistry ,Pharmaceutical Science ,Kinesins ,Mitosis ,Spindle Apparatus ,01 natural sciences ,Biochemistry ,Structure-Activity Relationship ,Cell Line, Tumor ,Drug Discovery ,Schizosaccharomyces ,Humans ,Molecular Biology ,Centrosome ,biology ,Dose-Response Relationship, Drug ,Molecular Structure ,010405 organic chemistry ,Chemistry ,Organic Chemistry ,biology.organism_classification ,Yeast ,0104 chemical sciences ,Cell biology ,010404 medicinal & biomolecular chemistry ,Schizosaccharomyces pombe ,Cancer cell ,Molecular Medicine ,KIFC1 ,Diterpenes ,Multipolar spindles - Abstract
Although cancer cells often harbor supernumerary centrosomes, they form pseudo-bipolar spindles via centrosome clustering, instead of lethal multipolar spindles, and thus avoid cell death. Kinesin-14 HSET/KIFC1 is a crucial protein involved in centrosome clustering. Accordingly, a compound that targets HSET could potentially inhibit cancer cell proliferation in a targeted manner. Here, we report three natural compounds derived from Solidago altissima that restored the growth of fission yeast cells exhibiting lethal HSET overproduction (positive screening), namely solidagonic acid (SA) (1), kolavenic acid analog (KAA: a stereo isomer at C-9 and C-10 of 6β-tigloyloxykolavenic acid) (2), and kolavenic acid (KA) (3). All three compounds suppressed fission yeast cell death and enabled reversion of the mitotic spindles from a monopolar to bipolar morphology. Compound 2, which exerted the strongest activity against HSET-overproducing yeast cells, also inhibited centrosome clustering in MDA-MB-231 human breast adenocarcinoma cells, which contained large numbers of supernumerary centrosomes. These natural compounds may be useful as bioprobes in studies of HSET function. Moreover, compound 2 is a prime contender in the development of novel agents for cancer treatment.
- Published
- 2019